Información de la revista
Vol. 43. Núm. 5.
Páginas 170-171 (septiembre - octubre 2019)
Vol. 43. Núm. 5.
Páginas 170-171 (septiembre - octubre 2019)
LETTERS TO THE EDITOR
Acceso a texto completo
Comments on the Anticholinergic Burden Calculator Web Tool. REPLY
Comentarios sobre la herramienta web Anticholinergic Burden Calculator. RÉPLICA
Visitas
974
Ángela Villalba-Moreno1, Eva Rocío Alfaro-Lara2, Susana Sánchez-Fidalgo3,
Autor para correspondencia
susana.sanchez.exts@juntadeandalucia.es

Author of correspondence, Susana Sánchez-Fidalgo, Hospital Universitario Valme, Ctra. de Cádiz, Km. 548,9,, 41014 Sevilla. Spain.
, Bernardo Santos-Ramos1
1 Pharmacy Service, University Hospital Virgen del Rocío, Seville
2 Andalusian Agency for Health Technology Assessment, Seville
3 Pharmacy Service, University Hospital Valme, Seville. Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Dear Domingo-Echaburu et al.:

First all, I would like to express my gratitude for your contribution to anticholinergic burden, in your case, for psychiatric patients. Your scientific research is valuable for improving understanding of the variability between anticholinergic scales according to the type of patient studied1.

We have reviewed your comment about Anticholinergic Drug Scale (ADS) update and you are correct. There was indeed an update of this scale in 2013, but unfortunately, it has not yet been published in the scientific community. Our research group contacted the author of the ADS scale, Ryan Carnahan. He sent us the latest version of the ADS as an attached file with important changes in anticholinergic drugs. We decided to add it to the Anticholinergic Burden Calculator2 after the author had given his consent due to the significant changes it makes, such as the inclusion of biperiden, fesoterodin and solifenacin, drugs with high anticholinergic potential. Recommendations to interpret the results obtained with the ADS scale have also been tested/approved. For Carnahan et al., it is important to focus on level 2 and 3 drugs as those with potentially clinically significant anticholinergic properties. They are fairly skeptical of level 1 drugs and the evidence on which those ratings are based. The side-effect profiles do not really suggest anticholinergic effects. Some of the evidence that led to those ratings is inconsistent with more recent studies. For example, Chew and colleagues tested a group of drugs and found that many of the drugs identified as anticholinergic by Larry Tune's earlier work did not have anticholinergic properties for their assays3,4. Tune's work was the basis for many of the level 1 ratings. However, not all of those drugs have been reevaluated. The bottom line is that it is preferable to ignore level 1 drugs unless the preference is to calculate the whole score.

On the other hand, we have the example of the Anticholinergic Cognitive Burden (ACB) scale, which was revised and updated in 2012 with important changes such as the inclusion of fesoterodin and solifenacin with a score of level 3. However, we were not able to include this in the Anticholinergic Burden Calculator for reasons of Copyright5.

Finally, we are pleased to inform you that our research group is currently working on a new update of the Anticholinergic Burden Calculator to include specific recommendations for clinicians to facilitate the optimization of pharmacotherapy. In addition, we plan to request express authorization from the authors of ACB to include the 2012 update and offer the information on anticholinergic load as completely and fully updated as possible.

Conflict of interests

No conflict of interest.

Bibliografía
[1]
Lertxundi U , Domingo-Echaburu S , Hernández R , Peral J , Medrano J .
Expert-based drug lists to measure anticholinergic burden: similar names, different results.
Psychogeriatrics, 13 (2013), pp. 17-24
[2]
Carnahan RM , Lund BC , Perry PJ , Pollock BG , Culp KR .
The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity.
J Clin Pharmacol, 46 (2006), pp. 1481-1486
[3]
Chew ML , Mulsant BH , Pollock BG , Lehman ME , Greenspan A , Mahmoud RA , et al.
Anticholinergic activity of 107 medications commonly used by older adults.
J Am Geriatr Soc, 56 (2008), pp. 1333-1341
[4]
Tune L .
Anticholinergic effects of medication in elderly patients.
J Clin Psychiatry, 62 (2001), pp. 11-14
[5]
Regenstrief Institute, Inc. Aging Brain Care. Anticholinergic Cognitive Burden Scale. 2012 Update; [Internet] 2012 [consultado 19/7/2019]. Disponible en: https://psnc.org.uk/lancashire-lpc/wp-content/uploads/sites/97/2014/02/Anticholinergic-burden-scale-2012.pdf
Copyright © 2019. Sociedad Española de Farmacia Hospitalaria
Descargar PDF
Idiomas
Farmacia Hospitalaria
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.